Dispatches from Korea

Inside Celltrion: a biosimilar success story built on landfill

By Dan Stanton

29-Aug-2016 - Last updated on 30-Aug-2016 at 12:56 GMT

Biopharma-Reporter visited the 'pioneers of the mAb biosimilar industry'

Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, Korea.

Biopharma-Reporter visited the 'pioneers of the mAb biosimilar industry'

Related news

Related products

Learn more about KLEPTOSE® BioPharma for your protein stability challenges

Roquette Pharma Solutions | 14-Jun-2019 | Case Study

Therapeutic proteins are inherently unstable and sensitive to temperature change, shearing, shaking, solvents, ionic strength, purity, protein concentration,...

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

The Power of Collaboration: M Lab™ Collaboration Centers

MilliporeSigma | 29-Oct-2018 | Business Advice

How can you bring your innovation strategy to life? Step into an M Lab™ Collaboration Center and bring life-saving therapies to market faster:
• Explore...

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....